Showing results (291-300 of 301) with videos related to

Sort By:
Pageof 31
JAMA Cardiology|November 3, 2021
Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical TrialDouglas L Mann, Michael M Givertz, Justin M Vader, et al.
Circulation. Cardiovascular Quality and Outcomes|January 12, 2021
The Cardiovascular Quality Improvement and Care Innovation Consortium: Inception of a Multicenter Collaborative to Improve Cardiovascular Care, Steven M Bradley, Srinath Adusumalli, et al.
Cureus|September 24, 2025
Surgical Outcomes of Open, Laparoscopic, and Robotic-Assisted Approaches for Stage I Endometrial Cancer: Insights From a Real-World Study by the Indian Gynecologic-Onco Study GroupVandana Jain, Jaydip Bhaumik, Rama Joshi, et al.
Gynecologic Oncology|June 4, 2024
Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trialGiorgio Valabrega, Bhavana Pothuri, Ana Oaknin, et al.
JACC. Heart Failure|July 10, 2020
Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE TrialDouglas L Mann, Stephen J Greene, Michael M Givertz, et al.
Cancer|April 15, 2023
Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT-OV26/GOG-3012 trialMansoor R Mirza, Antonio González-Martín, Whitney S Graybill, et al.
Gynecologic Oncology|February 7, 2024
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trialBhavana Pothuri, Sileny Han, Dana M Chase, et al.
Clinical Therapeutics|July 17, 2024
Niraparib Population Pharmacokinetics and Exposure-Response Relationships in Patients With Newly Diagnosed Advanced Ovarian CancerBradley J Monk, Ignacio Romero, Whitney Graybill, et al.
Gynecologic Oncology|May 13, 2022
Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 studyRoisin E O'Cearbhaill, Jose-Alejandro Pérez-Fidalgo, Bradley J Monk, et al.
The New England Journal of Medicine|September 29, 2019
Niraparib in Patients with Newly Diagnosed Advanced Ovarian CancerAntonio González-Martín, Bhavana Pothuri, Ignace Vergote, et al.
Pageof 31